SCHEMBL1171114

SCHEMBL1171114

O=C(O)CC(S)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 1/20 0.53
GABBR1 Q9UBS5 1/20 0.53
CYP2C19 P33261 2/20 0.48
CYP2D6 P10635 1/20 0.44
SRC P12931 1/20 0.44
CPA1 P15085 2/20 0.44
CPB1 P15086 1/20 0.44
CPA3 P15088 1/20 0.44
CPB2 Q96IY4 1/20 0.44
MAPT P10636 1/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43
FFAR1 O14842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL28282419 0.98 GABBR2 (0.52) GABBR2GABBR1CYP2C19CYP2D6SRC
Ethylene Glycol SCHEMBL1170971 0.94 GABBR2 (0.48) GABBR2GABBR1CYP2C19CYP2D6SRC
SCHEMBL999962 0.91 GABBR2 (0.42) GABBR2GABBR1CYP2C19CYP2D6LMNA
SCHEMBL1303811 0.89 GABBR2 (0.44) GABBR2GABBR1CYP2C19CYP2D6CPA1
SCHEMBL1171446 0.89 GABBR2 (0.44) GABBR2GABBR1CYP2C19CYP2D6CPA1
Glycerin SCHEMBL3192940 0.89 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1CPB1
Glycerin SCHEMBL3210246 0.89 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1CPB1
SCHEMBL1171222 0.89 GABBR2 (0.44) GABBR2GABBR1CYP2C19CYP2D6CPA1
Propylene Glycol SCHEMBL1171246 0.87 GABBR2 (0.43) GABBR2GABBR1CYP2C19MAPTFFAR1
SCHEMBL999007 0.87 GABBR2 (0.46) GABBR2GABBR1CYP2C19CYP2D6SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114835826-A Zwitterionic cellulose and preparation method and application thereof 深圳华源再生医学有限公司 2022-08-02 CN claimed
EP-3854786-B1 METHOD FOR PRODUCING AMINO ACID DERIVATIVES UBE CORP (JP) 2026-02-18 EP disclosed
US-12492293-B2 Multi-component systems for preparing foamed products ARKEMA FRANCE (FR) 2025-12-09 US disclosed
EP-3868740-B1 CARBOXYLIC ACID-TYPE LIPID, AND LIPID PARTICLE AND LIPID MEMBRANE CONTAINING CARBOXYLIC ACID-TYPE LIPID TORAY INDUSTRIES (JP) 2025-08-06 EP disclosed
US-12378450-B2 Adhesive for endoscope and cured product thereof, and endoscope and method for producing the same FUJIFILM CORPORATION (JP) 2025-08-05 US disclosed
US-20250205384-A1 HEMOSTATIC MATERIAL TORAY INDUSTRIES, INC. (JP) 2025-06-26 US disclosed
US-12325677-B2 Carboxylic acid-type lipid, and lipid particle and lipid membrane each comprising carboxylic acid-type lipid TORAY INDUSTRIES, INC. (JP) 2025-06-10 US disclosed
US-20250154361-A1 RECESS FILLING MATERIAL KIT, CURED PRODUCT THEREOF, AND RECESS FILLING METHOD RESONAC CORPORATION (JP) 2025-05-15 US disclosed
US-12281074-B2 Method for producing amino acid derivatives UBE CORPORATION (JP) 2025-04-22 US disclosed
CN-119707784-A Process for preparing amino acid derivatives 株式会社API 2025-03-28 CN disclosed
US-20100029876-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND SHOWA DENKO K.K. (JP) 2010-02-04 US disclosed
EP-2088163-A1 CURABLE COMPOSITION CONTAINING HYDROXYL GROUP-CONTAINING THIOL COMPOUND AND CURED PRODUCT THEREOF Showa Denko K.K. (JP) 2009-08-12 EP disclosed
EP-2030989-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING THIOL COMPOUND Showa Denko K.K. (JP) 2009-03-04 EP disclosed
US-20090023831-A1 Curable Composition Containing Thiol Compound SHOWA DENKO K.K. (JP) 2009-01-22 US disclosed
EP-1983017-A1 CURABLE COMPOSITION CONTAINING THIOL COMPOUND Showa Denko K.K. (JP) 2008-10-22 EP disclosed
JP-2003125795-A METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ACYLTHIO-3- PHENYLPROPIONIC ACIDS OR OPTICALLY ACTIVE 2-MERCAPTO-3- PHENYLPROPIONIC ACIDS MITSUBISHI GAS CHEM CO INC 2003-05-07 JP disclosed
EP-0528957-A4 FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS 1993-05-05 EP disclosed
EP-0528957-A1 FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-03-03 EP disclosed
WO-1991016889-A1 FIVE-MEMBERED RING ALKANOIC ACID LEUKOTRIENE ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1991-11-14 WO disclosed
US-4520196-A α-Mercaptophenylacetic acid derivatives of imidazole-containing compounds and analogues thereof AMERICAN HOME PRODUCTS CORPORATION (US) 1985-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205384-A1 HEMOSTATIC MATERIAL F2, F12, FGB GABBR2 2457/4885GABBR1 3100/4885CYP2C19 3942/4885
US-20100029876-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND TMT1A, CCNT1, MGMT GABBR2 4091/4885GABBR1 4296/4885CYP2C19 3376/4885
US-12325677-B2 Carboxylic acid-type lipid, and lipid particle and lipid membrane each comprising carboxylic acid-type lipid PLTP, F2, GP6 GABBR2 3234/4885GABBR1 3865/4885CYP2C19 2091/4885
US-12281074-B2 Method for producing amino acid derivatives PTGS2, PTGES, PTGES2 GABBR2 2458/4885GABBR1 3000/4885CYP2C19 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.